

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 May 2024 (02.05.2024)



(10) International Publication Number
WO 2024/092240 A1

(51) International Patent Classification:

A61K 31/4025 (2006.01) A61P 13/12 (2006.01)
A61K 31/4178 (2006.01) A61K 45/06 (2006.01)
A61K 31/513 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2023/078096

(22) International Filing Date:

27 October 2023 (27.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/420,305 28 October 2022 (28.10.2022) US
63/420,504 28 October 2022 (28.10.2022) US

(71) Applicants: CHINOOK THERAPEUTICS, INC.

[US/US]; 400 Fairview Avenue North, Suite 900,
Seattle, Washington 98109 (US). ADURO BIOTECH
HOLDINGS, EUROPE B.V. [NL/NL]; Molenstraat 40F,
5242 HA Rosmalen (NL).

(72) Inventor: KING, Andrew James; 400 Fairview Avenue

North, Suite 900, Seattle, Washington 98109 (US).

(74) Agent: BATES, Caleb A. et al.; Fish & Richardson P.C.,

P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: TREATMENT OF IGA NEPHROPATHY USING AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN APRIL BINDING ANTIBODY



* Up to 20 subjects with eGFR 20 to <30 mL/min/1.72m² will be enrolled in an exploratory cohort for a total n=292

FIG. 1

(57) Abstract: The present disclosure relates to the use of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and isolated antibodies, including antigen-binding fragments thereof, which bind human APRIL for the treatment of IgA nephropathy.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*